Also known as RNA.
FDA approves a six-month antisense-oligonucleotide therapy with option for self-administration; phase III showed 19% functional cure in patients with HBsAg ≤3000 IU/ml.
New single-molecule platform uses SBX chemistry and reusable CMOS nanopore sensors to deliver same-day whole‑genome sequencing, open-source analysis and flexible workflows.
CRS offers R&D-grade pDNA, RNA and LNP production, construct design, lipid screening and analytical services for preclinical studies, with seamless scale-up to GMP clinical supply.
Recognised for multinational coordination, on-site technical support, strategic integration and punctual logistics across the Americas, boosting sustainable performance and supply‑chain reliability
